EGFR and non-small cell lung carcinoma: Based on the encouraging antitumor activity in our current study, we propose that this novel regimen of apatinib plus gefitinib could be another promising combinational first‐line therapy and would be beneficial for patients who were diagnosed with the advanced EGFR‐mutant NSCLC.